bioAffinity Technologies Inc
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping bioAffinity Technologies stock as it may not significantly rise or fall.
Financial Health
bioAffinity Technologies is generating steady revenue and cash flow, indicating a positive financial outlook.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BIAF
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage catalysts
Clinical data, regulatory decisions and partnership news can materially move the share price, though outcomes are uncertain and volatility can be high.
R&D and funding
Progress in diagnostics development could unlock value but typically requires ongoing funding; capital raises can dilute existing shareholders.
Liquidity and size
A small market capitalisation and thin trading can amplify price swings and make buying or selling large positions harder—consider diversification.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
